Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Arcus Biosciences (NYSE:RCUS) will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022, at 9:20 a.m. PT.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California. The fireside chat will take place on Thursday, June 16th, 2022 at 9:20 a.m. PT.
A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
